A Phase 3 interventional study of Lurasidone and Placebo in Bipolar I Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 105 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-07.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multi-center, randomized, placebo-controlled, flexible-dose, parallel-group study designed to evaluate the efficacy and safety of lurasidone (in combination with lithium or divalproex) for the maintenance treatment of bipolar I disorder in subjects with or without rapid cycling and /or psychotic features.
This study is to evaluate the efficacy and safety of lurasidone (in combination with lithium or divalproex) for the maintenance treatment of bipolar I disorder in subjects with or without rapid cycling and/or psychotic features.
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
First submitted after Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd..
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Open-label Phase
, 4th Ed., Text Revision (DSM-IV-TR) diagnosis of bipolar I disorder
•≥ 1 manic, mixed manic, or depressed episode in past 2 years
Double-blind Phase
Inclusion Criteria:
Exclusion Criteria:
Open Label Phase
Double Blind Phase
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lurasidone
Drug: Placebo
Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
20-80 mg flexible dose
Time to Recurrence of Mood Event During the Double Blind Treatment Phase
A mood event is defined as one of the following during the double-blind phase: (1) Fulfilled Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision (DSM-IV-TR) criteria for manic, mixed manic, hypomanic, or depressive episode. (2) Required treatment intervention for manic, mixed manic, hypomanic, or depressive symptoms with any antipsychotic (other than study drug), antidepressant, mood stabilizer (other than lithium or divalproex), anxiolytic agents, benzodiazepine (beyond dosage allowed for anxiety, agitation, or insomnia). (3) Psychiatric hospitalization for any bipolar mood episode. (4) Young Mania Rating Scale (YMRS) or Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥ 18 or Clinical Global Impression Bipolar Version, Severity of Illness (CGI BP S) score ≥ 4 at 2 consecutive assessments no more than 10 days apart. (5) Discontinuation from the study because of a mood event (as determined by the Investigator).
Time frame: 28 weeks (up to 33 weeks)
Time to All-cause Discontinuation
Time frame: 28 weeks (up to 33 weeks)
Time to Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
Time frame: 28 weeks (up to 33 weeks)
Percentage of Subjects Who Experience a Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode
Time frame: 28 weeks
Change From Double-blind Baseline to Week 28 (LOCF) in CGI-BP-S Overall Score
The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1=Normal, not at all ill, to 7=Among the most extremely ill patients. a higher score is associated with greater illness severity.
Time frame: Double-blind Baseline to week 28
Change From Double -Blind Baseline to Week 28 (LOCF) in CGI-BP-S Mania Score
The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A high score is associated with greater illness severity
Time frame: Double-blind Baseline to week 28
Change From Double-blind Baseline to Week 28 (LOCF) in CGI+-BP-S Depression Score
The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with a greater illness severity.
Time frame: Double-blind Baseline to week 28
Change From Double-blind Baseline to Week 28 (LOCF) in YMRS Total Score
the YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of maia.
Time frame: Double-blind Baseline to week 28
Change From Double-blind Baseline to Week 28 (LOCF) in MADRS Total Score
The MADRS consists of 10 items, each rated on a Likert scale, from 0=Normal to 6=Most Severe. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depressive symptoms.
Time frame: Double-blind Baseline to week 28
Change Fro Double-blind Baseline to Week 28 (LOCF) in QIDS-SR(16) Total Score
The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms.
Time frame: Double-blind Baseline to week 28
Change From Double-blind Baseline to Week 28 (LOF) in PANSS Positive Symptom (PANNS-P) Subscale Score
The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Time frame: Double-blind Baseline to week 28
Change From Double-blind Baseline to Week 28 (LOCF) in SDS Total Score
The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing.
Time frame: Double-blind Baseline to week 28
Change From Double-blind Baseline to Week 28 (LOCF) in PIRS-2 Total Score
The PIRS-2 is a 2-item self-report of insomnia assessed via a computer interface. Each item is scored from 0-3. The PIRS-2 total score is calculated as the sum of the 2 items. The PIRS total score ranges from 0 to 6. Higher scores are associated with greater severity of insomnia.
Time frame: Double-blind Baseline to week 28
Change From Double-blind Baseline to Week 28 (LOCF) in Q-LES-Q-SF Percent Maximum Possible Score
The Q-LES-Q-SF is a 16-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living. The questionnaire was developed and validated for use in depressed outpatient subjects and has eight summary scales that reflect major areas of functioning: physical health, mood, leisure time activities, social relationships, general activities, work, household duties and school/coursework. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The Q-LES-Q-SF percentage maximum possible score is calculated as 100 × (Raw Score - 14 \[Minimum Score\]) / (70 \[Maximum Score\] - 14 \[Minimum Score\]). Higher percent maximum scores indicate better quality of life.
Time frame: Double-blind Baseline to week 28
| Milestone | Lurasidone 20-80 mg Flexible Dose | Placebo | All Subjects |
|---|---|---|---|
| Started | 0 | 0 | 965 |
| Completed | 0 | 0 | 503 |
| Not completed | 0 | 0 | 462 |
| Withdrew: Adverse event | 0 | 0 | 59 |
| Withdrew: Lack of efficacy | 0 | 0 | 107 |
| Withdrew: Lost to follow-up | 0 | 0 | 76 |
| Withdrew: Protocol violation | 0 | 0 | 45 |
| Withdrew: Withdrawal by subject | 0 | 0 | 112 |
| Withdrew: Did not meet criteria for db phase | 0 | 0 | 16 |
| Withdrew: Terminated at study completion | 0 | 0 | 5 |
| Withdrew: Mood episode | 0 | 0 | 42 |
| Milestone | Lurasidone 20-80 mg Flexible Dose | Placebo | All Subjects |
|---|---|---|---|
| Started | 246 | 250 | 0 |
| Completed | 166 | 150 | 0 |
| Not completed | 80 | 100 | 0 |
| Withdrew: Adverse event | 8 | 5 | 0 |
| Withdrew: Lost to follow-up | 5 | 7 | 0 |
| Withdrew: Protocol violation | 1 | 11 | 0 |
| Withdrew: Protocol violation | 16 | 12 | 0 |
| Withdrew: Terminated at study completion | 2 | 0 | 0 |
| Withdrew: Recurrence of mood event | 48 | 64 | 0 |
| Withdrew: Administrative | 0 | 1 | 0 |
A mood event is defined as one of the following during the double-blind phase: (1) Fulfilled Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision (DSM-IV-TR) criteria for manic, mixed manic, hypomanic, or depressive episode. (2) Required treatment intervention for manic, mixed manic, hypomanic, or depressive symptoms with any antipsychotic (other than study drug), antidepressant, mood stabilizer (other than lithium or divalproex), anxiolytic agents, benzodiazepine (beyond dosage allowed for anxiety, agitation, or insomnia). (3) Psychiatric hospitalization for any bipolar mood episode. (4) Young Mania Rating Scale (YMRS) or Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥ 18 or Clinical Global Impression Bipolar Version, Severity of Illness (CGI BP S) score ≥ 4 at 2 consecutive assessments no more than 10 days apart. (5) Discontinuation from the study because of a mood event (as determined by the Investigator).
| Days | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Time to Recurrence of Mood Event During the Double Blind Treatment Phase | NA (NA to NA) | 207 (207 to NA) |
| Days | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Time to All-cause Discontinuation | 225 (204 to 233) | 207 (207 to 216) |
| Days | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Time to Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode | NA (NA to NA) | NA (207 to NA) |
| percentage of participants | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Percentage of Subjects Who Experience a Recurrence of a Manic, Mixed Manic, Hypomanic, or Depressed Episode | 16.7 | 21.6 |
The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1=Normal, not at all ill, to 7=Among the most extremely ill patients. a higher score is associated with greater illness severity.
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change From Double-blind Baseline to Week 28 (LOCF) in CGI-BP-S Overall Score | 0.40 ± 0.085 | 0.49 ± 0.085 |
The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A high score is associated with greater illness severity
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change From Double -Blind Baseline to Week 28 (LOCF) in CGI-BP-S Mania Score | 0.10 ± 0.062 | 0.21 ± 0.062 |
The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and ranges from 1=Normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with a greater illness severity.
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change From Double-blind Baseline to Week 28 (LOCF) in CGI+-BP-S Depression Score | 0.35 ± 0.082 | 0.42 ± 0.081 |
the YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of maia.
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change From Double-blind Baseline to Week 28 (LOCF) in YMRS Total Score | 1.0 ± 0.43 | 1.8 ± 0.43 |
The MADRS consists of 10 items, each rated on a Likert scale, from 0=Normal to 6=Most Severe. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depressive symptoms.
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change From Double-blind Baseline to Week 28 (LOCF) in MADRS Total Score | 3.0 ± 0.57 | 3.5 ± 0.57 |
The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms.
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change Fro Double-blind Baseline to Week 28 (LOCF) in QIDS-SR(16) Total Score | 0.9 ± 0.27 | 1.1 ± 0.27 |
The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change From Double-blind Baseline to Week 28 (LOF) in PANSS Positive Symptom (PANNS-P) Subscale Score | 0.2 ± 0.13 | 0.3 ± 0.13 |
The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing.
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change From Double-blind Baseline to Week 28 (LOCF) in SDS Total Score | 0.4 ± 0.59 | 0.6 ± 0.61 |
The PIRS-2 is a 2-item self-report of insomnia assessed via a computer interface. Each item is scored from 0-3. The PIRS-2 total score is calculated as the sum of the 2 items. The PIRS total score ranges from 0 to 6. Higher scores are associated with greater severity of insomnia.
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change From Double-blind Baseline to Week 28 (LOCF) in PIRS-2 Total Score | 0.4 ± 0.10 | 0.5 ± 0.10 |
The Q-LES-Q-SF is a 16-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living. The questionnaire was developed and validated for use in depressed outpatient subjects and has eight summary scales that reflect major areas of functioning: physical health, mood, leisure time activities, social relationships, general activities, work, household duties and school/coursework. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The Q-LES-Q-SF percentage maximum possible score is calculated as 100 × (Raw Score - 14 \[Minimum Score\]) / (70 \[Maximum Score\] - 14 \[Minimum Score\]). Higher percent maximum scores indicate better quality of life.
| units on a scale | Lurasidone 20-80 mg Flexible Dose | Placebo |
|---|---|---|
| Change From Double-blind Baseline to Week 28 (LOCF) in Q-LES-Q-SF Percent Maximum Possible Score | -1.70 ± 1.022 | -2.07 ± 1.035 |
Collected over For all subjects column: during open label phase (up to 20 weeks) For 7 lurasidone + Li/VPA and placebo +Li/VPA columns: during double blind phase (up to 28 weeks).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone 20-80 mg Flexible Dose | — | 13/246 (5.3%) | 81/246 (32.9%) |
| Placebo | — | 11/250 (4.4%) | 81/250 (32.4%) |
| All Subjects | — | 41/962 (4.3%) | 474/962 (49.3%) |
| Event | Lurasidone 20-80 mg Flexible Dose | Placebo | All Subjects |
|---|---|---|---|
| ManiaPsychiatric disorders | 2/246 | 3/250 | 5/962 |
| DepressionPsychiatric disorders | 2/246 | 1/250 | 10/962 |
| Suicidal IdeationPsychiatric disorders | 2/246 | 0/250 | 2/962 |
| Bipolar 1 DisorderPsychiatric disorders | 1/246 | 2/250 | 2/962 |
| CholelithiasisHepatobiliary disorders | 1/246 | 1/250 | 0/962 |
| AppendicitisInfections and infestations | 1/246 | 0/250 | 0/962 |
| HypokalaemiaMetabolism and nutrition disorders | 1/246 | 0/250 | 0/962 |
| Bipolar DisorderPsychiatric disorders | 1/246 | 0/250 | 0/962 |
| Intentional Self InjuryPsychiatric disorders | 1/246 | 0/250 | 0/962 |
| Suicide AttemptPsychiatric disorders | 1/246 | 0/250 | 2/962 |
| Event | Lurasidone 20-80 mg Flexible Dose | Placebo | All Subjects |
|---|---|---|---|
| NauseaGastrointestinal disorders | 0/246 | 0/250 | 111/962 |
| Weight IncreasedInvestigations | 24/246 | 13/250 | 0/962 |
| HeadacheNervous system disorders | 21/246 | 17/250 | 88/962 |
| AkathisiaNervous system disorders | 9/246 | 8/250 | 80/962 |
| InsomniaPsychiatric disorders | 9/246 | 16/250 | 77/962 |
| SomnolenceNervous system disorders | 0/246 | 4/250 | 69/962 |
| VomitingGastrointestinal disorders | 0/246 | 0/250 | 59/962 |
| NasopharyngitisInfections and infestations | 15/246 | 12/250 | 39/962 |
| TremorNervous system disorders | 15/246 | 11/250 | 43/962 |
| DiarrhoeaGastrointestinal disorders | 0/246 | 0/250 | 53/962 |
| Age, Categorical(Participants) | Lurasidone 20-80 mg Flexible Dose | Placebo | Total |
|---|---|---|---|
| <=18 years | 2 | 0 | 2 |
| Between 18 and 65 years | 232 | 242 | 474 |
| >=65 years | 12 | 8 | 20 |
| Age, Continuous(years) | Lurasidone 20-80 mg Flexible Dose | Placebo | Total |
|---|---|---|---|
| Mean | 45.7 ± 12.43 | 43.2 ± 12.18 | 44.4 ± 12.36 |
| Sex: Female, Male(Participants) | Lurasidone 20-80 mg Flexible Dose | Placebo | Total |
|---|---|---|---|
| Female | 136 | 143 | 279 |
| Male | 110 | 107 | 217 |
| Ethnicity (NIH/OMB)(Participants) | Lurasidone 20-80 mg Flexible Dose | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 41 | 38 | 79 |
| Not Hispanic or Latino | 205 | 212 | 417 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Lurasidone 20-80 mg Flexible Dose | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 6 | 7 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 23 | 21 | 44 |
| White | 213 | 216 | 429 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 4 | 8 |
| Region of Enrollment(participants) | Lurasidone 20-80 mg Flexible Dose | Placebo | Total |
|---|---|---|---|
| Argentina | 19 | 19 | 38 |
| Russian Federation | 30 | 31 | 61 |
| Hungary | 13 | 15 | 28 |
| United States | 73 | 76 | 149 |
| Japan | 5 | 5 | 10 |
| Czech Republic | 23 | 24 | 47 |
| Poland | 22 | 21 | 43 |
| Slovakia | 4 | 3 | 7 |
| Bulgaria | 20 | 20 | 40 |
| Chile | 9 | 11 | 20 |
| France | 8 | 6 | 14 |
| Serbia | 20 | 19 | 39 |
Showing the first 100 of 105 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2011, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →